Results 21 to 30 of about 3,560 (171)

Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature

Hematology/Oncology and Stem Cell Therapy, 2022
The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a ...
Jude Howaidi, Abdullah M. AlRajhi, Ali Howaidi, Fouad H. AlNajjar, Imran K. Tailor   +4 more
doaj   +3 more sources

Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP)

Platelets, 2017
Background: Thrombopoietin-receptor-agonists (TPO-RAs) increase platelet production in Immune Thrombocytopenia (ITP) by stimulating Mpl. The effect of TPO-RAs on inflammatory cytokine production in ITP patients has not been well investigated.
Sif Gudbrandsdottir, Waleed Ghanima, Claus H Nielsen, Xingmin Feng, Hans C Hasselbalch, James Bussel   +5 more
doaj   +2 more sources

Thrombopoietin receptor agonists for the treatment of inherited thrombocytopenia

Haematologica, 2020
Michael Makris
doaj   +5 more sources

Thrombopoietin receptor agonists in pharmacotherapy of pediatric immune thrombocytopenia

Research Results in Pharmacology, 2023
Introduction: Thrombopoietin receptor agonists are commonly second-line drugs in immune thrombocytopenia (ITP) pharmacotherapy in children and prescribed for chronic ITP refractory to first-line therapy.
Olga S. Levchenkova, Viktoriya V. Vorobieva, Vasiliy E. Novikov, Tatiana I. Legonkova, Elena N. Volkova   +4 more
doaj   +1 more source

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice [PDF]

Pharmaceutics, 2022
Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity. In this study, we examined the effects of romiplostim, one of the TPO-RAs, on pregnant mice. The mice were injected subcutaneously with
Kensaku Nakai, Takuya Misugi, Kohei Kitada, Yasushi Kurihara, Mie Tahara, Akihiro Hamuro, Akemi Nakano, Masayasu Koyama, Yukimi Kira, Daisuke Tachibana   +9 more
openaire   +3 more sources

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure [PDF]

Exploration of Drug Science, 2023
Thrombocytopenia is one of the most frequent implications of liver cirrhosis. This condition, when present in the severe form [platelet count (PLT) less than 50 × 109/L] correlates, with an increased risk of bleeding during the main diagnostic ...
Davide Scalabrini, Paolo Sciuto, Cristina Felicani, Antonia Rudilosso, Pietro Andreone   +4 more
doaj   +1 more source

Peptide agonists of the thrombopoietin receptor [PDF]

Stem Cells, 1998
We have screened a variety of L-amino acid peptide libraries against the extracellular domain of the human thrombopoietin (HuTPO) receptor, c-Mpl. A large number of peptide ligands were recovered and categorized into two families. Peptides from each family compete with the binding of HuTPO and with the binding of peptides from the other familiy ...
W J, Dower, S E, Cwirla, P, Balasubramanian, P J, Schatz, D P, Baccanari, R W, Barrett   +5 more
openaire   +2 more sources

Combination of two target agonists of the thrombopoietin and thrombopoietin receptor in the treatment of elderly patients with refractory immune thrombocytopenia

Cancer Pathogenesis and Therapy, 2023
Immune thrombocytopenia (ITP) is common in the elderly. Because of the coexistence of multiple diseases, there are many reservations regarding corticosteroid use in the elderly. Thrombopoietin (TPO) and its analogs can promote platelet production, but it
Jundong Zhang, Zining Wang, Haoran Chen, Xuechun Lu   +3 more
doaj   +1 more source

Primary immune thrombocytopenia in children

Pediatria Polska, 2021
Primary immune thrombocytopenia (ITP) is usually a benign and self-limiting disease in children. Due to the complex pathogenesis involving different immunological processes, its course may be unpredictable.
Agnieszka Książek, Tomasz Szczepański
doaj   +1 more source

Thrombopoietin receptor agonists in hereditary thrombocytopenias [PDF]

Journal of Thrombosis and Haemostasis, 2018
Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought.
Rodeghiero, F., Pecci, A., Balduini, C. L.   +2 more
openaire   +3 more sources